Discovery of a unique Mycobacterium tuberculosis protein through proteomic analysis of urine from patients with active tuberculosis

Nira R. Pollock, Rakesh K. Dhiman, Nada Daifalla, Maha Farhat, Antonio Campos‐NetoMicrobes 2018 · DOI

TL;DR

Researchers have identified a novel protein fragment from Mycobacterium tuberculosis (Mtb) in the urine of TB patients. This unique peptide, found to be encoded by a rare genetic mutation, shows promise as a potential biomarker for diagnosing TB and could indicate a wider global distribution of certain Mtb strains than previously understood.

What Problem Does This Paper Address?

Diagnosing active tuberculosis (TB) often relies on sputum analysis, which can be challenging, especially in resource-limited settings or for individuals who cannot produce sufficient sputum. The development of non-invasive diagnostic tools, such as those detecting pathogen-specific biomarkers in urine ("antigenuria"), is a critical area of research. While antigenuria has been observed for various pathogens, identifying specific, reliable biomarkers for Mycobacterium tuberculosis (Mtb) that are present in urine and correlate with active disease remains an ongoing challenge. This paper aims to discover such a biomarker by analyzing proteins in the urine of TB patients.

Methods

The study employed a multi-pronged approach:

  • Proteomic Analysis of Urine: Urine samples from TB patients were concentrated and subjected to SDS-PAGE. Protein bands were then excised and analyzed using mass spectrometry (LC-MS/MS) to identify peptide sequences.
  • Bioinformatic Analysis: Identified peptide sequences were compared against protein databases (e.g., using BLAST) to determine their origin and homology to known proteins. Phylogenetic analysis was used to understand the evolutionary relationships of Mtb strains carrying the identified gene.
  • Gene Synthesis and Protein Expression: The gene encoding the C-terminal portion of the identified Mtb protein was synthesized and expressed in E. coli. The recombinant protein was then purified for use in immunological assays.
  • ELISA: Enzyme-linked immunosorbent assays (ELISA) were performed to detect antibodies against the purified Mtb protein C-terminus in serum samples from TB patients and healthy controls.

Datasets

  • Urine Samples: Two urine samples from patients with active pulmonary TB in Zimbabwe.
  • Serum Samples: 60 serum samples from TB patients from Peru (n=20), Vietnam (n=20), and South Africa (n=20). For each country, 10 samples were from smear-positive and 10 from smear-negative patients.
  • Control Sera: Pooled normal human serum (NHS) from commercial sources (ThermoFisher Scientific, Sigma-Aldrich) and from individual healthy donors from Brazil (n=3).
  • Public Mtb Sequence Data: Shotgun sequence files from 5310 Mtb isolates from the NCBI sequence read archive were analyzed to identify the prevalence of the gene encoding the discovered protein.

Key Insights and Ideas

  • Antigenuria as a Diagnostic Avenue: The paper reinforces the concept that pathogen-derived molecules in urine can serve as valuable diagnostic markers, even when the primary infection is not in the urinary tract.
  • Discovery of a Novel Mtb Peptide: Through a rigorous proteomic approach, a unique 21-mer peptide from an Mtb protein was identified in the urine of TB patients. This peptide's uniqueness is a key finding.
  • Genetic Basis for Uniqueness: The peptide is encoded by a protein (TBCG_03312) that arises from a rare insertion point mutation in the Rv3368c gene of certain Mtb strains (C strain and MTB423). This mutation leads to a novel C-terminus with no known homology to other proteins.
  • Potential for Wider Distribution: Despite the apparent rarity of the genetic mutation, serological data (ELISA) suggests that antibodies recognizing this unique Mtb protein C-terminus are present in TB patients from diverse geographical regions (Peru, Vietnam, South Africa). This implies that Mtb strains carrying this mutation might be more widespread than initially thought.
  • Immunogenicity of the Novel Protein: The presence of antibodies against the recombinant C-terminus in a significant proportion of TB patients indicates that this protein is immunogenic during Mtb infection.

Key Results

  • A unique 21-mer Mtb peptide (VVLGLTVPGGVELLPGVALPR) was identified in the urine of two TB patients from Zimbabwe.
  • This peptide showed 100% homology to the protein TBCG_03312 from the Mtb C strain and 95% homology to Mtb oxidoreductase from the MTB423 clinical isolate.
  • Phylogenetic analysis confirmed that the C strain and MTB423 are phylogenetically distinct from the reference H37Rv strain, with the unique C-terminus arising from an insertion point mutation.
  • ELISA results showed that none of the healthy control sera reacted with the recombinant TBCG_03312 C-terminus.
  • In contrast, approximately 35% (Peru), 60% (Vietnam), and 75% (South Africa) of sera from TB patients recognized the recombinant C-terminus.

Limitations and Future Work

  • Geographic Limitations of Urine Samples: The initial discovery of the peptide in urine was from patients in Zimbabwe. While serological data suggests wider distribution, direct detection of the peptide in urine from other regions was not performed.
  • Lack of Control Sera from Endemic Regions: The study acknowledges that it would be beneficial to test sera from healthy individuals (with and without latent TB) from Zimbabwe, Peru, Vietnam, and South Africa to better understand baseline reactivity.
  • Uncertainty of Specific Mtb Strain: The study cannot definitively pinpoint the specific Mtb strain responsible for the serological reactivity in patients from Peru, Vietnam, and South Africa, only that it is likely related to strains carrying the unique C-terminus.
  • Bioinformatics Pipeline Conservatism: The authors note that their bioinformatics pipeline for variant detection might have been conservative, potentially missing some relevant variations.
  • Future Work: The authors propose further studies including:
  • Molecular detection (mass spectrometry or RT-PCR) of the unique C-terminus in Mtb cultures from various isolates.
  • Production of specific antibodies to the polypeptide.
  • Development of a sensitive capture ELISA for antigen detection.
  • Clinical investigation to determine if such an assay can aid in TB diagnosis.
  • Further analysis of finished genomes from specific Mtb lineages to better interpret genetic variations.

Summary updated

Abstract

Identification of pathogen-specific biomarkers present in patients' serum or urine samples can be a useful diagnostic approach. In efforts to discover Mycobacterium tuberculosis (Mtb) biomarkers we identified by mass spectroscopy a unique 21-mer Mtb peptide sequence (VVLGLTVPGGVELLPGVALPR) present in the urines of TB patients from Zimbabwe. This peptide has 100% sequence homology with the protein TBCG_03312 from the C strain of Mtb (a clinical isolate identified in New York, NY, USA) and 95% sequence homology with Mtb oxidoreductase (MRGA423_21210) from the clinical isolate MTB423 (identified in Kerala, India). Alignment of the genes coding for these proteins show an insertion point mutation relative to Rv3368c of the reference H37Rv strain, which generated a unique C-terminus with no sequence homology with any other described protein. Phylogenetic analysis utilizing public sequence data shows that the insertion mutation is apparently a rare event. However, sera from TB patients from distinct geographical areas of the world (Peru, Vietnam, and South Africa) contain antibodies that recognize a purified recombinant C-terminus of the protein, thus suggesting a wider distribution of isolates that produce this protein.
BibTeX
@inproceedings{pollock2018discovery,
  author = {Nira R. Pollock and Rakesh K. Dhiman and Nada Daifalla and Maha Farhat and Antonio Campos‐Neto},
  title = {{Discovery of a unique Mycobacterium tuberculosis protein through proteomic analysis of urine from patients with active tuberculosis}},
  booktitle = {Microbes},
  year = {2018},
  doi = {10.1016/j.micinf.2017.12.011},
}
Figure